The marked difference in HER2-positivity rates between DCIS and IBC implies that HER2 amplification is an early oncogenic event, acting as a driver of neoplastic cell proliferation rather than as an instigator of transition from in situ to invasive carcinoma [13]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.